Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen

Table 2

Univariate and multivariate analysis using a multilevel linear regression model.

Primary Analysis: 12 Months
Mean Change in BCVA
	Univariate		Multivariate
	Beta (95% CI)	P-value	Beta (95% CI)	P-value
Treatment Group	-3.39 (-8.04, 1-26)	0.153	-3.86 (-8.75, 1.02)	0.121
Age	0.16 (-0.16, 0.48)	0.324	0.11 (-0.24, 0.45)	0.545
No Inj (12 mo)	1.09 (-1.50, 3.68)	0.408	1.88 (-0.76, 4.52)	0.163
BCVA baseline	-0.04 (-0.17, 0.09)	0.577	-0.10 (-0.23, 0.04)	0.169
CRT baseline	-0.02 (-0.04, -0.001)	0.037	-0.03 (-0.04, -0.01)	0.010
Mean Change in CRT
	Univariate		Multivariate
	Beta (95% CI)	P-value	Beta (95% CI)	P-value
Treatment Group	49.20 (-7.56, 105.95)	0.009	24.44 (-5.86, 54.47)	0.011
Age	3.51 (-0.30, 7.32)	0.071	0.73 (-1.49, 2.98)	0.493
No Inj (12 mo)	9.28 (22.55, 41.10)	0.568	9.14 (-7.15, 25.5)	0.270
BCVA baseline	2.76 (-0.17, 0.09)	<0.001	0.46 (-0.21, 2.01)	0.016
CRT baseline	-0.80 (-0.92, -0.67)	<0.001	-0.72 (-0.86, -0.59)	<0.001
Secondary Analysis: 18 months
Mean change in BCVA
	Univariate		Multivariate
	Beta (95% CI)	P-value	Beta (95% CI)	P-value
Treatment Group	-2.86 (-7.72, 2.00)	0.249	-1.42 (-6.44, 3.61)	0.581
Age	-0.02 (-0.36, 0.32)	0.925	-0.06 (-0.41, 0.29)	0.743
No Inj (18 mo)	0.50 (-1.17, 2.16)	0.561	1.01 (-0.72, 2.74)	0.254
BCVA baseline	-0.02 (-0.16, 0.12)	0.764	-0.08 (-0.22, 0.07)	0.309
CRT baseline	-0.01 (-0.03, -0.01)	0.158	-0.02 (-0.03, 0.001)	0.073
Mean change in CRT
	Univariate		Multivariate
	Beta (95% CI)	P-value	Beta (95% CI)	P-value
Treatment Group	64.09 (7.08, 121.09)	0.028	39.85 (1.66, 78.04)	0.041
Age	3.44 (-0.50, 7.49)	0.087	-0.43 (-3.13, 2.28)	0.756
No Inj (18 mo)	3.00 (-17.38, 23.37)	0.773	6.55 (-6.67, 19.78)	0.332
BCVA baseline	1.72 (0.08, 3.35)	0.040	-0.16 (-1.30, 0.97)	0.778
CRT baseline	-0.81 (-0.95, -0.66)	<0.001	-0.79 (-0.96, -0.63)	<0.001

BCVA: best corrected visual acuity, No Inj: number of injections, CRT: central retinal thickness, mo: months